Literature DB >> 9988191

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

M Bray1, K Davis, T Geisbert, C Schmaljohn, J Huggins.   

Abstract

The Zaire subtype of Ebola virus (EBO-Z) is lethal for newborn mice, but adult mice are resistant to the virus, which prevents their use as an animal model of lethal Ebola infection. We serially passed EBO-Z virus in progressively older suckling mice, eventually obtaining a plaque-purified virus that was lethal for mature, immunocompetent BALB/c and C57BL/6 inbred and ICR (CD-1) outbred mice. Pathologic changes in the liver and spleen of infected mice resembled those in EBO-Z-infected primates. Virus titers in these tissues reached 10(9) pfu/g. The LD50 of mouse-adapted EBO-Z virus inoculated into the peritoneal cavity was approximately 1 virion. Mice were resistant to large doses of the same virus inoculated subcutaneously, intradermally, or intramuscularly. Mice injected peripherally with mouse-adapted or intraperitoneally with non-adapted EBO-Z virus resisted subsequent challenge with mouse-adapted virus.

Entities:  

Mesh:

Year:  1999        PMID: 9988191     DOI: 10.1086/514292

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  72 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

4.  Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

Authors:  Yasuteru Sakurai; Andrey A Kolokoltsov; Cheng-Chang Chen; Michael W Tidwell; William E Bauta; Norbert Klugbauer; Christian Grimm; Christian Wahl-Schott; Martin Biel; Robert A Davey
Journal:  Science       Date:  2015-02-27       Impact factor: 47.728

5.  Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.

Authors:  Loreen L Lofts; Jay B Wells; Sina Bavari; Kelly L Warfield
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques.

Authors:  Kendra J Alfson; Laura E Avena; Michael W Beadles; Hilary Staples; Jerritt W Nunneley; Anysha Ticer; Edward J Dick; Michael A Owston; Christopher Reed; Jean L Patterson; Ricardo Carrion; Anthony Griffiths
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

7.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Authors:  Zachary A Bornholdt; Hannah L Turner; Charles D Murin; Wen Li; Devin Sok; Colby A Souders; Ashley E Piper; Arthur Goff; Joshua D Shamblin; Suzanne E Wollen; Thomas R Sprague; Marnie L Fusco; Kathleen B J Pommert; Lisa A Cavacini; Heidi L Smith; Mark Klempner; Keith A Reimann; Eric Krauland; Tillman U Gerngross; Karl D Wittrup; Erica Ollmann Saphire; Dennis R Burton; Pamela J Glass; Andrew B Ward; Laura M Walker
Journal:  Science       Date:  2016-02-18       Impact factor: 47.728

8.  Ebola: history, treatment, and lessons from a new emerging pathogen.

Authors:  Kevin S Harrod
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-12       Impact factor: 5.464

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

10.  An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.

Authors:  Dapeng Li; Tan Chen; Yang Hu; Yu Zhou; Qingwei Liu; Dongming Zhou; Xia Jin; Zhong Huang
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.